Fig 1.
English-language reports of studies of thrombopoietic agents identified from Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, PubMed, Embase, ClinicalTrials.gov, HTAs, a hand search of bibliographies, and clinical input were assessed for eligibility in a two-part process per a prespecified protocol to identify relevant articles for analysis. ASCO, American Society of Clinical Oncology; ASH, American Society of Hematology; AWMSG, All Wales Medicines Strategy Group; CADTH, Canadian Agency for Drugs and Technologies in Health; HTA, health technology assessment; NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium; thrombopoietic agent, thrombopoietin receptor agonist.
Table 1.
Characteristics of studies that met the eligibility criteria for assessment.
Fig 2.
Meta-analyses of efficacy and safety outcomes.
n = number of studies with a study arm reporting the endpoint of interest. N = total number of patients in study arms reporting the endpoint of interest. Meta-analyses were performed for efficacy and safety data from 30 studies that had outcomes data reported in ≥ 3 studies for thrombopoietic agents versus control (comparator, placebo, or no treatment) for the prevention or treatment of CIT across all tumor types and summary proportions (point estimates) and 95% CIs (horizontal bars) of patients experiencing the outcome calculated. Heterogeneity was assessed using Cochran’s Q test and the I2 statistic, and individual study weights created using the inverse of their variance. n represents the number of studies with a study arm reporting the endpoint of interest. CI, confidence interval; CIT, chemotherapy-induced thrombocytopenia; I2, degree of heterogeneity; thrombopoietic agent, thrombopoietin receptor agonist.
Table 2.
Meta-analysis results for efficacy and safety outcomes for thrombopoietic agent versus placebo or no treatment by combined and individual thrombopoietic agents.